Humacyte, Inc. (NASDAQ:HUMA) Stock Has Average Price Target of $6.54

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given an average recommendation of “Moderate Buy” by the seven analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.54.

Several research firms have recently commented on HUMA. Benchmark reduced their price target on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a research report on Thursday, August 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. TD Cowen lowered their price target on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a report on Wednesday, June 17th. BTIG Research restated a “buy” rating and issued a $2.00 price objective on shares of Humacyte in a report on Wednesday, August 12th. Finally, Wall Street Zen cut shares of Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th.

Hedge Funds Weigh In On Humacyte

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Humacyte in the second quarter valued at approximately $3,777,000. Alyeska Investment Group L.P. acquired a new stake in shares of Humacyte in the second quarter valued at $4,700,000. GSA Capital Partners LLP acquired a new stake in shares of Humacyte in the second quarter valued at $785,000. Beacon Pointe Advisors LLC purchased a new stake in shares of Humacyte in the 2nd quarter valued at $28,000. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Humacyte in the 2nd quarter valued at $180,506. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Stock Performance

Shares of HUMA opened at $0.52 on Wednesday. The company has a current ratio of 6.21, a quick ratio of 5.74 and a debt-to-equity ratio of 2.07. Humacyte has a 12-month low of $0.50 and a 12-month high of $2.55. The firm has a 50-day moving average price of $0.62 and a 200 day moving average price of $0.78. The firm has a market capitalization of $144.87 million, a P/E ratio of -1.06 and a beta of 2.44.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%.The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million. Sell-side analysts forecast that Humacyte will post -0.4 EPS for the current year.

Humacyte Company Profile

Humacyte, Inc is a biotechnology company developing and manufacturing bioengineered human tissues for use in regenerative medicine. Its technology platform is designed to produce off-the-shelf, implantable tissues that can be stored and transported for use when needed, potentially reducing reliance on tissue obtained directly from patients or human donors.

The company’s primary product is SYMVESS, an acellular tissue-engineered vascular graft designed to replace or repair damaged blood vessels.